These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38926371)

  • 1. [Efficacy and safety of dust mite subcutaneous immunotherapy in children with allergic asthma： a prospective randomized controlled study].
    Wang YN; Lu SQ; Chen H; Li YQ; Lu HY; Zhu H; Chang M
    Zhongguo Dang Dai Er Ke Za Zhi; 2024 Jun; 26(6):559-566. PubMed ID: 38926371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy comparison and safety analysis of subcutaneous specific immunotherapy with standardized house dust mite allergen in patients with single and multiple allergic rhinitis].
    Huang HH; Xu C; Liu L; Chai RN
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jun; 56(6):774-783. PubMed ID: 35785859
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of house dust mite subcutaneous immunotherapy in polysensitized children with allergic asthma.
    Zhang P; Jia Y; Jing Z; Huang J; Wu H; Sun X
    Pulm Pharmacol Ther; 2023 Feb; 78():102187. PubMed ID: 36603742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and safety study of standardized mite allergen specific immunotherapy with no reduction during maintenance in children with respiratory allergic disease].
    Liang Y; Zhong Y; Li YY; Zhu LP; Yang LF; Ou SX; Chen ZG; Zhang PP
    Zhonghua Yu Fang Yi Xue Za Zhi; 2024 Jun; 58(6):768-777. PubMed ID: 38955723
    [No Abstract]   [Full Text] [Related]  

  • 5. [Therapeutic efficacy of 3-year subcutaneous immunotherapy in asthmatic children allergic to mite].
    Li L; Hui Y; Qian J; Guo Y; Zhang XL; Zhang XJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 May; 15(5):368-71. PubMed ID: 23676940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and adverse reactions to subcutaneous immunotherapy in children with allergic rhinitis/asthma.
    Duman Senol H; Topyildiz E; Ekici B; Gulen F; Demir E
    Int J Pediatr Otorhinolaryngol; 2022 Nov; 162():111292. PubMed ID: 36007303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial.
    Karakoc-Aydiner E; Eifan AO; Baris S; Gunay E; Akturk E; Akkoc T; Bahceciler NN; Barlan IB
    J Investig Allergol Clin Immunol; 2015; 25(5):334-42. PubMed ID: 26727762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD).
    Pfaar O; Bachert C; Bufe A; Buhl R; Ebner C; Eng P; Friedrichs F; Fuchs T; Hamelmann E; Hartwig-Bade D; Hering T; Huttegger I; Jung K; Klimek L; Kopp MV; Merk H; Rabe U; Saloga J; Schmid-Grendelmeier P; Schuster A; Schwerk N; Sitter H; Umpfenbach U; Wedi B; Wöhrl S; Worm M; Kleine-Tebbe J; Kaul S; Schwalfenberg A
    Allergo J Int; 2014; 23(8):282-319. PubMed ID: 26120539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of house dust mite subcutaneous immunotherapy in preschool children with respiratory allergic diseases.
    Yang Y; Ma D; Huang N; Li W; Jiang Q; Wang Y; Wang X; Yang L; Zhu R
    Ital J Pediatr; 2021 Apr; 47(1):101. PubMed ID: 33892756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Predictive model of curative effect of mite subcutaneous immunotherapy in 5-18 years of age patients with allergic asthma].
    Duan QN; Zhao DY; Yan M; Liu F; Chen MX; Yang LH
    Zhonghua Er Ke Za Zhi; 2022 Apr; 60(4):291-296. PubMed ID: 35385932
    [No Abstract]   [Full Text] [Related]  

  • 11. Augmented type 2 inflammatory response in allergic rhinitis patients experiencing systemic reactions to house dust mite subcutaneous immunotherapy.
    Ji P; Yang L; Zhu L; Hu L; Wang Y; Shi C; Jiang Q; Huang N; Yang Y; Chen H; Zhu R
    Pediatr Allergy Immunol; 2024 Aug; 35(8):e14207. PubMed ID: 39092594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intra-cervical lymphatic immunotherapy for dust mite-induced allergic rhinoconjunctivitis in children: a 3-year prospective randomized controlled trial.
    Wang Q; Wang K; Qin Y; Huang W; Li Y; Yu Q; Xiong Y; Guo Y; Zheng R; Tang J
    Front Immunol; 2023; 14():1144813. PubMed ID: 37593733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of subcutaneous immunotherapy in mite-sensitized subjects with asthma: a meta-analysis.
    Lu Y; Xu L; Xia M; Li Y; Cao L
    Respir Care; 2015 Feb; 60(2):269-78. PubMed ID: 25389355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. House Dust Mite Sublingual Immunotherapy for Pediatric Patients With Allergic Asthma.
    Richards JR; Stumpf JL
    Ann Pharmacother; 2018 Oct; 52(10):1019-1030. PubMed ID: 29642713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial.
    Eifan AO; Akkoc T; Yildiz A; Keles S; Ozdemir C; Bahceciler NN; Barlan IB
    Clin Exp Allergy; 2010 Jun; 40(6):922-32. PubMed ID: 20100188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of semi-depot house dust mite allergen extract in children and adolescents with allergic rhinitis and asthma.
    Xiang L; Liu F; Zhi L; Jiang W; Liu C; Xie H; Zhou X; Sun Y; Zheng Y; Zhu R; Tao Z; Xia W; Lai H; Wei Q; Cheng L; Tang Y; Xu R; Huang H; Zhou Q; Chang P
    Immunotherapy; 2021 Feb; 13(3):227-239. PubMed ID: 33317341
    [No Abstract]   [Full Text] [Related]  

  • 17. The changes in different symptom scores during subcutaneous immunotherapy in Chinese house dust mite allergic patients: a two-year, observational study.
    Tu Y; Zhang H; Zhao L; Jin P; Zi X; Li T; Shi L; Zhi L
    J Laryngol Otol; 2019 Mar; 133(3):213-219. PubMed ID: 30674357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of the effect of early subcutaneous specific immunotherapy on the levels of dust mite allergen-specific antibodies and polyunsaturated fatty acid metabolism].
    Li SY; Zheng PY; Zhai YY; Zhang YD; Gan H; Huang HM; Luo WT; Jiang MY; Zhang GZ; Zhong RF; Cheng ZK; Sun SX; Sun BQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2024 Jun; 58(6):778-790. PubMed ID: 38955724
    [No Abstract]   [Full Text] [Related]  

  • 19. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes.
    Keles S; Karakoc-Aydiner E; Ozen A; Izgi AG; Tevetoglu A; Akkoc T; Bahceciler NN; Barlan I
    J Allergy Clin Immunol; 2011 Oct; 128(4):808-815.e7. PubMed ID: 21641635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
    Calderon MA; Casale TB; Nelson HS; Demoly P
    J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.